Effectiveness and tolerability of switching from 20% subcutaneous immunoglobulin to hyaluronidase-facilitated subcutaneous immunoglobulin 10% in the same patients with secondary hypogammaglobulinemia.

Yoshinori Hashimoto, Saaya Hosoda, Hiromi Omura, Takayuki Tanaka

Abstract read

In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yoshinori HashimotoDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan. 98069yh@jichi.ac.jp.ORCID http://orcid.org/0000-0002-3374-9814

Saaya HosodaDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.

Hiromi OmuraDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.

Takayuki TanakaDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE AND

methodsThe availability of high-concentration 20% subcutaneous immunoglobulin (SCIG 20%) and hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) has recently expanded therapeutic options for immunoglobulin replacement therapy in patients with secondary immunodeficiency (SID). The present study aimed to confirm the effectiveness and tolerability of each SCIG formulation in eight patients with SID switched from SCIG 20% to fSCIG 10% and to inform SCIG selection in clinical practice.

resultsThe number of infection events varied among patients and was generally low during each SCIG administration. At the individual patient level, no significant difference was observed in infection rates between SCIG 20% and fSCIG 10%. Local adverse events occurred more frequently with fSCIG 10% than with SCIG 20%. Local adverse events with fSCIG 10% persisted as treatment continued but remained mild.

conclusionThese results suggest that dosing interval preferences, adverse event tolerability, and shared decision-making are important considerations in SCIG selection.

Indexed as

AgammaglobulinemiaDrug SubstitutionHyaluronoglucosaminidaseImmunoglobulinsAdultFemaleHumansInjections, SubcutaneousMaleMiddle AgedTreatment OutcomeHyaluronoglucosaminidaseImmunoglobulins20% subcutaneous immunoglobulinHyaluronidase-facilitated subcutaneous immunoglobulin 10%Immunoglobulin replacement therapySecondary immunodeficiency

Identifiers

PMID42160001

DOI10.1007/s12185-026-04224-z

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.